| Risk of exercise-induced hypoglycaemia in patients with type 2 diabetes on intensive insulin therapy: comparison of insulin glargine with NPH insulin as basal insulin supplement. | |
| | |
MedLine Citation:
|
PMID: 18692269 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
AIM: Hypoglycaemia is the most common adverse event associated with intensive conventional insulin therapy (ICT). This study compared the risk of exercise-related hypoglycaemia in type 2 diabetes patients receiving either basal insulin glargine or NPH insulin. METHODS: In a prospective trial, 122 ICT patients (glargine n=60, NPH n=62) had a standardized treadmill test, monitored by capillary lactate concentration. Blood glucose (BG) profiles were performed the day before, during and the day after the exercise test, with the patients on a strict carbohydrate-defined diet. All patients had been on a stable ICT scheme for at least three months and had an HbA1c below 7.5%. RESULTS: BG at the beginning of the exercise test, BG decline and lowest BG during the test were comparable between the two groups. The episodes of mild hypoglycaemia (BG<3.3 mmol/l) and amounts of additional carbohydrate intake due to mild symptoms of hypoglycaemia (BG 3.3-5.0 mmol/l) were not significantly different. No episodes of hypoglycaemia occurred during several hours after the exercise. CONCLUSIONS: Moderate physical activity can be recommended for well-controlled type 2 diabetes patients receiving ICT, independently of glargine or NPH as basal insulin and without risk of exercise-induced hypoglycaemia. |
| | |
Authors:
|
Ursula Plöckinger; Mendaha Topuz; Brigitte Riese; Thomas Reuter |
Related Documents
:
|
12831339 - Insulin analogues and other developments in insulin therapy for diabetes. 12055019 - Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (lantus)... 15244099 - Effect of continuous subcutaneous insulin infusion vs multiple daily insulin injection ... 22795319 - Does fructose consumption contribute to non-alcoholic fatty liver disease? 20001569 - Management of severe hypoglycaemia: cultural similarities, differences and resource con... 3280369 - The adjustment of diet and insulin dose during long-term endurance exercise in type 1 (... 11397859 - Metabolic and steroidogenic alterations related to increased frequency of polycystic ov... 3053749 - Quantitation of forearm glucose and free fatty acid (ffa) disposal in normal subjects a... 17720889 - New pharmacologic approaches to treating diabetic retinopathy. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2008-08-08 |
Journal Detail:
|
Title: Diabetes research and clinical practice Volume: 81 ISSN: 1872-8227 ISO Abbreviation: Diabetes Res. Clin. Pract. Publication Date: 2008 Sep |
Date Detail:
|
Created Date: 2008-08-18 Completed Date: 2008-11-18 Revised Date: 2008-11-21 |
Medline Journal Info:
|
Nlm Unique ID: 8508335 Medline TA: Diabetes Res Clin Pract Country: Ireland |
Other Details:
|
Languages: eng Pagination: 290-5 Citation Subset: IM |
Affiliation:
|
Interdisziplinäres Stoffwechsel-Centrum, Campus Virchow-Klinikum, Charité-Universitätsmedizin Berlin, Germany. ursula.ploeckinger@charite.de |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Blood Glucose / drug effects, metabolism* Diabetes Mellitus, Type 2 / blood*, drug therapy* Drug Administration Schedule Exercise* Hemoglobin A, Glycosylated / metabolism Humans Hypoglycemic Agents / administration & dosage, therapeutic use Insulin / administration & dosage, analogs & derivatives*, therapeutic use Insulin, NPH / administration & dosage, therapeutic use* Middle Aged |
| Chemical | |
Reg. No./Substance:
|
0/Blood Glucose; 0/Hemoglobin A, Glycosylated; 0/Hypoglycemic Agents; 0/glargine; 11061-68-0/Insulin; 53027-39-7/Insulin, NPH |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Association of sterol regulatory element-binding protein-1c gene polymorphism with type 2 diabetes m...
Next Document: Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.